文献速递淋巴瘤

奥妥珠单抗单药治疗CAR-T细胞治疗后进展的复发/难治性弥漫大B细胞淋巴瘤:ELM-1研究主要分析

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
PubMed 文献 · Blood · 2025-01-01

ELM-1研究预设的CAR-T后扩展队列纳入60例CAR-T治疗后进展的复发/难治性弥漫大B细胞淋巴瘤患者,接受奥妥珠单抗(CD20×CD3双特异性抗体)静脉给药。中位随访16.2个月,客观缓解率48.3%,完全缓解率31.7%,中位缓解持续时间14.8个月,中位无进展生存期4.8个月,中位总生存期10.2个月;最常见治疗中出现不良事件为细胞因子释放综合征(48.3%,无≥3级事件)。

要点

  • CAR-T后进展的复发/难治性弥漫大B细胞淋巴瘤患者接受奥妥珠单抗单药,客观缓解率48.3%,完全缓解率31.7%。
  • 中位缓解持续时间14.8个月,中位完全缓解持续时间未达到,中位无进展生存期4.8个月,中位总生存期10.2个月。
  • 细胞因子释放综合征发生率48.3%且无≥3级事件,未报告免疫效应细胞相关神经毒性综合征,≥3级感染12例(20.0%)。

核心结论

  • 奥妥珠单抗单药在CAR-T治疗后进展的复发/难治性弥漫大B细胞淋巴瘤患者中显示出令人鼓舞的疗效和总体可控的安全性,支持其作为CAR-T后即用型选择的潜力。

研究设计与样本

  • ELM-1研究预设的CAR-T后扩展队列,60例CAR-T治疗后疾病进展的复发/难治性弥漫大B细胞淋巴瘤患者接受奥妥珠单抗静脉给药,每周4个周期后维持治疗直至进展。
  • 主要终点为独立中心审查评估的客观缓解率;中位既往治疗线数为3(范围2-9),71.7%对CAR-T难治,48.3%在CAR-T治疗后90天内复发。
  • 试验注册号NCT02290951。

主要发现

  • 中位随访16.2个月,客观缓解率48.3%,完全缓解率31.7%。
  • 缓解率在不同既往CAR-T产品和CAR-T治疗后复发时间之间相似。
  • 中位缓解持续时间14.8个月,中位完全缓解持续时间未达到;中位无进展生存期4.8个月,中位总生存期10.2个月。
  • 最常见治疗中出现不良事件为细胞因子释放综合征(48.3%;无≥3级事件);未报告免疫效应细胞相关神经毒性综合征病例。
  • ≥3级感染发生于12例患者(20.0%),其中2例为COVID-19。

临床怎么用

  • 原文结论支持奥妥珠单抗单药作为CAR-T治疗后进展的复发/难治性弥漫大B细胞淋巴瘤患者的即用型选择潜力,未给出具体推荐等级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post-CAR-T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR-Ts. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression. The primary end point was objective response rate (ORR) by independent central review. The median number of prior lines of therapy was 3 (range, 2-9), 71.7% were refractory to CAR-Ts, and 48.3% relapsed within 90 days of CAR-T therapy. After a median follow-up of 16.2 months, ORR and complete response (CR) rate were 48.3% and 31.7%, respectively. Responses were similar across prior CAR-T products and time to relapse on CAR-T therapy. Median duration of response was 14.8 months and median duration of CR was not reached. Median progression-free survival and overall survival were 4.8 and 10.2 months, respectively. The most common treatment-emergent adverse event was cytokine release syndrome (48.3%; no grade ≥3 events). No cases of immune effector cell-associated neurotoxicity syndrome were reported. Grade ≥3 infections occurred in 12 patients (20.0%), 2 of which were COVID-19. Odronextamab monotherapy demonstrated encouraging efficacy and generally manageable safety, supporting its potential as an off-the-shelf option for patients after CAR-T therapy. This trial was registered at www.clinicaltrials.gov as #NCT02290951.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Topp MS, Matasar M, Allan JN, et al. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study. Blood. 2025. PMID: 39786390. doi:10.1182/blood.2024027044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。